Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
life sciences
national blog main
andrew berens
archive
avapritinib
biotech
blueprint medicines
boehringer ingelheim
boston
boston blog main
cancer
deciphera pharmaceuticals
eli lilly
empagliflozin
europe
europe blog main
europe top stories
gastrointestinal stromal tumor
gist
gleevec
imatinib
indiana blog main
indiana top stories
medical
medicine
new york blog main
new york top stories
regorafenib
research
ripretinib
slgt2 inhibitor
steve hoerter
stivarga
sunitinib
sutent
svb leerink
type 1 diabetes
type 2 diabetes
What
approval
3
×
drug
fda
3
×
type
3
×
announced
cancer
administration
bid
blood
blueprint
boehringer
brand
called
chasing
deadly
deciphera
diabetes
eli
expand
fallen
fast
filing
food
forms
gi
ingelheim
lilly
marketed
medicine
medicine’s
morning
new
patients
pharamceuticals
plans
rejects
seek
selinexor
short
sold
Language
unset
Current search:
type
×
fda
×
approval
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@slashgear.com
4 years ago
The FDA just fast-tracked this new blood cancer treatment
